I've long entertained the idea that a Johnson&Johnson buyout of the DurAVR is a distinct possibility as they have said themselves that the cardiac medtech space is a big priority for them and their actions over the last couple of years support their words..... The TAVR space is a behemoth of a market so it only makes sense that sooner or later J&J will focus their attention there.
I listened to a very interesting interview with Scott Kirkland, MD of EMVision the other day where he talked about how big global healthcare companies very often prefer to wait (and spend the extra $500 million+) to acquire technologies once they are proven and just before/at the start of commercialisation rather than the lower $ perhaps even a short period of time before that.... This is the situation I believe we find ourselves in now. Our competitors and interested potential acquirers KNOW how good we are although their company culture/philosophy dictates that waiting for the slam dunk, even if it's going to be more expensive, is the safer way to play things.
AVR Price at posting:
$15.62 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)